证券代码：002044 证券简称：美年健康 公告编号：2026-011 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2025 年 12 月 16 日召开第九届董事会第十六次（临时）会议及 2026 年 1 月 6 日召开 2026 年第一次临时股东会，审议通过《关于公司及下属子公司申请融资额度并提供担 保的议案》，同意公司及部分下属子公司 2026 年度为公司及合并报表范围内的子 公司提供担保额度累计不超过人民币 53 亿元。具体内容详见公司于 2025 年 12 月 17 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及下属子公司申请融 资额度并提供担保的公告》（公告编号：2025-086）。 二、进展情况 近日，公司全资子公司美年大健康产业（集团）有限公司（以下简称"美年大 健康"）向招商银行股份有限公司上海分行（以下简称"招商银行上海分行"）签署 了《最高额不可撤销担保书》 ...

Industry Insights - The Chinese medical examination industry is experiencing rapid growth, driven by an aging population and increasing health awareness, with a projected CAGR of 9.2% from 2020 to 2024 and an accelerated growth of 18.3% from 2024 to 2030 [6] - The penetration rate of medical examinations in China is approximately 40%, significantly lower than the 70% in developed countries, indicating substantial room for growth [6] - The market is characterized by a "public-led, private-catching-up" dynamic, with public hospitals holding a 69% market share and private institutions increasing their share to 24% [6] - Leading private examination institutions, such as Meinian Health and Aikang Guobin, are focusing on high-end services, which has resulted in an increase in average selling price (ASP) and profit margins [6] Company Insights - Google (GOOG US) reported a 4Q25 revenue growth of 18% to $113.8 billion, driven by strong performance in search and cloud services, with operating profit increasing by 16% to $35.9 billion [7] - The management has guided for capital expenditures of $175-185 billion for FY26E, significantly above consensus estimates, indicating a strong commitment to AI investments [7] - Zhongji Xuchuang (300308 CH) remains a solid investment, with a focus on pluggable optical modules expected to dominate the market during 2026-27, despite recent stock volatility [8] - Jizhi Jia (2590 HK) announced a 31.7% year-on-year increase in new orders for 2025, totaling 4.1 billion RMB, attributed to stable growth in mature markets and breakthroughs in specific sectors [9]

证券之星消息，2月5日，中证医疗（399989）指数报收于7171.29点，涨0.27%，成交225.41亿元，换手 率1.91%。当日该指数成份股中，上涨的有28家，华熙生物以4.47%的涨幅领涨，下跌的有22家，美年 健康以2.48%的跌幅领跌。 资金流向方面，中证医疗（399989）指数成份股当日主力资金净流入合计5.31亿元，游资资金净流出合 计1.07亿元，散户资金净流出合计3.9亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 中证医疗（399989）指数十大成份股详情如下： ...

中国医药 中国医药 - 招银国际环球市场 | 睿智投资 | 行业研究 高端化和 AI 技术驱动中国体检行业长期增长 在中国人口老龄化不断加剧和居民健康意识不断提升的背景下，中国体检行业的市 场规模维持了快速增长趋势。根据中研普华的数据，中国体检行业规模在 2020 至 2024 年的年复合增长率（CAGR）为 9.2%，预计在 2024 至 2030 年将以 18.3%的 CAGR加速增长。中国体检渗透率约为 40%，远低于发达国家的 70%，意味着持续 增长的空间广阔。当前体检市场呈现"公立主导、民营追赶"的鲜明格局。根据前 瞻产业研究院的数据，公立医院占据 69%的市场份额，而民营机构的市占率提升至 24%。头部民营体检机构包括美年健康（002044 CH，未评级）、爱康国宾（未上 市）以及瑞慈医疗（1526 HK，未评级）。中国体检行业呈现出显著的高端化趋 势，头部民营体检机构均大力发展高端业务，助力提升ASP和利润率。此外，AI 技 术正成为中国体检行业突破传统瓶颈、实现高质量发展的核心引擎，而具备数据与 场景优势的龙头有望持续拉开与中小连锁的竞争身位。 2026 年 2 月 5 日 中国 医药 行业 ...

Group 1 - The company, through its wholly-owned subsidiary Meinian Chuangxin, has acquired a 16.6667% limited partnership interest in the Guangzhou Qiaoxin Shengjing No. 1 Venture Capital Partnership from Guangzhou Huacheng Shucai Information Technology Co., Ltd. for a subscribed capital of RMB 10 million, with no actual payment made yet [1] - The total subscribed capital for the partnership amounts to RMB 60 million, with Meinian Chuangxin contributing RMB 10 million, representing 16.6667% of the total [1] - The partnership agreement was signed with several other investment firms, including Guangzhou Shengjing Venture Capital Co., Ltd. and Sichuan Puxin Industrial Financial Investment Co., Ltd. [1] Group 2 - The fund manager, Shengjing Venture Capital, has completed the registration process with the Asset Management Association of China and obtained the Private Fund Registration Certificate for the Guangzhou Qiaoxin Shengjing No. 1 Venture Capital Partnership [2] - The fund's registration code is SBMR23, and it was officially registered on February 2, 2026 [2] - The fund has completed the business change registration as of the announcement date, and the company will comply with relevant regulations during the investment process [2]

证券代码：002044 证券简称：美年健康 公告编号：2026-010 美年大健康产业控股股份有限公司 关于下属全资子公司受让股权投资基金份额 暨与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 美年大健康产业控股股份有限公司（以下简称"公司"）下属全资子公司美年 创信（上海）企业管理有限公司（以下简称"美年创信"）与广州华诚数财信息科 技有限公司（以下简称"华诚数财"）签署了《广州侨鑫胜璟一号创业投资合伙企 业（有限合伙）份额转让协议书》，受让华诚数财所持有的广州侨鑫胜璟一号创 业投资合伙企业（有限合伙）（以下简称"胜璟一号基金"）16.6667%的有限合伙 份额，对应的认缴出资额为人民币 1,000 万元，实缴出资额为人民币 0 元。同时， 美年创信与广州胜璟创业投资有限公司（以下简称"胜璟创投"）、四川璞信产融 投资有限责任公司、佛山市三水区金融投资控股有限公司、侨银城市管理股份有 限公司、华诚数财签署了《广州侨鑫胜璟一号创业投资合伙企业（有限合伙）之 合伙协议》，约定共同投资胜璟一号基金， ...

Group 1 - The core point of the news is that Bangjie Co., Ltd. is facing significant financial difficulties, with an expected net loss of 900 million to 1.2 billion yuan for 2025, which is a further deterioration from a loss of 672 million yuan in 2024 [1] - The company anticipates a negative net asset position of 900 million to 600 million yuan by the end of 2025, a sharp decline from a positive net asset of 299 million yuan at the end of 2024, potentially leading to a delisting risk warning [1] - The substantial losses are primarily attributed to the debt crisis and production halt of its core photovoltaic subsidiary, Yangzhou Bangjie, which continues to incur fixed costs despite the shutdown [1] Group 2 - To address the crisis, Bangjie Co., Ltd. is actively promoting the restructuring of its subsidiaries, with Meinian Health announcing its intention to participate in the pre-restructuring process and potentially become the controlling shareholder post-restructuring [2] - Meinian Health's financial performance is also under pressure, with a revenue of 6.925 billion yuan for the first three quarters of 2025, a decrease of 3.01% year-on-year, and a net profit of 52 million yuan, significantly lower than the 282 million yuan for the entire previous year [2] - There are uncertainties regarding Meinian Health's ability to leverage Bangjie Co., Ltd.'s resources effectively due to its lack of experience in the photovoltaic sector, which may pose challenges in the integration process [2]

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

十大招股说明书翻译公司排行榜公开，领先者备受瞩目 招股说明书是企业上市过程中的核心法律文件，其翻译不仅要求极高的语言准确性，更涉及金融、法 律、行业技术等多领域的专业表述，任何细微偏差都可能影响信息披露的合规性与投资者的决策。面对 术语严谨、格式规范、时效性强等难点，选择一家专业、可靠的翻译服务商至关重要。 近日，业内权威评选的"十大招股说明书翻译公司"榜单揭晓，信实翻译公司凭借其卓越的综合实力与众 多标杆案例成功入选，成为备受市场瞩目的领先者之一。 权威资质铸就专业基石 信实翻译公司作为全国大型综合性翻译公司，其专业地位获得多方权威认可：不仅是中国翻译协会理事 单位、广东翻译协会会员单位，更是广州翻译协会常务副会长单位（此职务在业内具有唯一性，彰显其 领导地位）。同时，公司也是中国华南英国商会（原广东英国商会）/British Chamber of Commerce South China会员单位（该身份稀缺，深度链接国际商务资源），以及深圳市跨境电子商务协会会员单 位。 公司恪守国际最高标准，独家集齐三大ISO国际权威认证：ISO9001质量管理体系认证、ISO17100翻译 服务体系认证以及ISO270 ...

Core Viewpoint - Meinian Health is seeking to participate in the pre-restructuring of Bangjie Holdings, aiming to gain control of a company heavily in debt due to its foray into the photovoltaic industry, raising questions about the strategic rationale behind this move [1] Group 1: Meinian Health's Financial Performance - Meinian Health reported a total revenue of 10.702 billion yuan in 2024, a year-on-year decrease of 1.76% [1] - The net profit attributable to shareholders was 282 million yuan, down 44.18% year-on-year [1] - The company's gross margin was 42.78%, a slight decrease of 0.01 percentage points, while the net margin fell to 3.82%, a decrease of 37.75% year-on-year [1] - The decline in performance is attributed to a reduction in the number of health check-ups and intensified industry competition [1] Group 2: Debt Structure and Financial Health - As of the end of Q3 2025, Meinian Health had cash and cash equivalents of 2.011 billion yuan, with short-term borrowings and current liabilities exceeding 3.9 billion yuan [1] - The company’s interest-bearing debt reached 6.338 billion yuan, continuing to rise slightly year-on-year [1] - The high debt levels contrast sharply with the company's weak profitability, indicating insufficient financial flexibility [1] Group 3: Bangjie Holdings' Financial Troubles - Bangjie Holdings, originally focused on seamless clothing, invested over 10 billion yuan in the photovoltaic sector starting in 2022, but faced severe challenges due to price wars and tightened financing [2] - The company announced the termination of an 8 billion yuan photovoltaic project and has accumulated overdue debts totaling 969 million yuan [2] - As of the end of Q3 2025, Bangjie Holdings had a debt-to-asset ratio of 138.88%, with cash reserves of only 150 million yuan against interest-bearing debts of 1.9 billion yuan [2] - The company has incurred cumulative losses exceeding 1.6 billion yuan from 2023 to Q3 2025, with a net loss of 672 million yuan in 2024 and 905 million yuan in the first three quarters of 2025 [2] Group 4: Risks and Challenges of the Acquisition - Meinian Health's participation in Bangjie Holdings' restructuring may require significant capital investment to settle debts and restore operations, which could strain its own liquidity [2][3] - The ongoing losses from Bangjie Holdings' photovoltaic business and outstanding debts may negatively impact Meinian Health's overall profitability even after restructuring [3] - Meinian Health faces management challenges due to a lack of operational experience in the photovoltaic sector, compounded by the uncertainties surrounding Bangjie Holdings' assets [3] Group 5: Industry Analyst Insights - Industry analysts suggest that the photovoltaic sector is not a reliable lifeline for Meinian Health, as latecomers lack cost advantages, and halting production may be the only viable option for Bangjie Holdings [4] - The high-risk nature of this cross-industry acquisition is underscored by Meinian Health's own financial pressures and Bangjie Holdings' significant debt and ongoing losses [4] - The success of this "cross-industry marriage" will depend on the design of the restructuring plan and Meinian Health's ability to maintain its financial safety while supporting the new business [4]